VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a study to understand if taking VTX002 daily as a tablet orally is safe and effective
in participants diagnosed with moderate to severe ulcerative colitis (UC). Approximately 180
participants will take VTX002 Dose A, VTX002 Dose B, or matching placebo, once daily.
The study consists of a 28-day Screening Period (to see if a participant qualifies for the
study), a 13-week double-blind period (a participant receives either active Dose A, Dose B or
Placebo), a 39-week OLE Treatment Period (all participants receive active treatment) and a
2-week Follow-Up Period